drugset
drugset / Trial / NCT01001403

Effect of Nafamostat on Postreperfusion Syndrome (PRS)

NCT01001403 ↗

Phase 4 Completed 62 enrolled Seoul National University Hospital
RandomizedParallel-groupTriple-blindPrevention

Summary

This study intends to see the effect of nafamostat on the attenuation of postreperfusion syndrome (PRS) that frequently occurs during liver transplantation.

Timeline

Start
2009-03
Primary completion
2010-03
Completion
2010-04

Drugs

EvaluationDrugModalityDoseRoute
Subject Nafamostat Small molecule 0.2 mg/kg Intravenous

Indications

No indication recorded.